THE PDE4 INHIBITOR TANIMILAST SHOWS DISTINCT IMMUNOMODULATORY PROPERTIES ASSOCIATED WITH A TYPE 2 ENDOTYPE AND CD141 UPREGULATION
H. Nguyen (Brescia (BS), Italy), V. Salvi (Brescia (BS), Italy), L. Tiberio (Brescia (BS), Italy), M. Govoni (Parma (PR), Italy), G. Villetti (Parma (PR), Italy), M. Civelli (Parma (PR), Italy), I. Barbazza (Brescia (BS), Italy), C. Gaudenzi (Brescia (BS), Italy), M. Passari (Brescia (BS), Italy), T. Schioppa (Brescia (BS), Italy), F. Sozio (Brescia (BS), Italy), A. Dal Prete (Brescia (BS), Italy), S. Sozzani (Rome (RM), Italy), D. Bosisio (Brescia (BS), Italy), F. Facchinetti (Parma (PR), Italy)
Source: International Congress 2022 – Clinical and translational studies of asthma and COPD: novel mechanisms
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
H. Nguyen (Brescia (BS), Italy), V. Salvi (Brescia (BS), Italy), L. Tiberio (Brescia (BS), Italy), M. Govoni (Parma (PR), Italy), G. Villetti (Parma (PR), Italy), M. Civelli (Parma (PR), Italy), I. Barbazza (Brescia (BS), Italy), C. Gaudenzi (Brescia (BS), Italy), M. Passari (Brescia (BS), Italy), T. Schioppa (Brescia (BS), Italy), F. Sozio (Brescia (BS), Italy), A. Dal Prete (Brescia (BS), Italy), S. Sozzani (Rome (RM), Italy), D. Bosisio (Brescia (BS), Italy), F. Facchinetti (Parma (PR), Italy). THE PDE4 INHIBITOR TANIMILAST SHOWS DISTINCT IMMUNOMODULATORY PROPERTIES ASSOCIATED WITH A TYPE 2 ENDOTYPE AND CD141 UPREGULATION. 2258
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
|
|